In this article
BPC-157 is a synthetic 15-amino-acid peptide studied mainly in animals for its effects on tendon, muscle, gut and blood-vessel repair. The reported benefits come almost entirely from preclinical work, and high-quality human trials are still limited. It is not FDA-approved for any condition.
- BPC-157 is a lab-made fragment modeled on a protective protein sequence associated with gastric juice.
- Animal studies point to effects on blood-vessel growth, nitric oxide signaling, growth factors and collagen.
- Most claims about faster recovery are anecdotal; clinical evidence in people is thin.
- Signal IQ lists research protocols of about 500 mcg subcutaneously, once daily, for 8 to 12 weeks.
- It is a research compound, so any decision belongs with a qualified clinician.
What is BPC-157?
BPC-157, short for Body Protection Compound-157, is a chain of 15 amino acids. Its sequence is based on a protective protein found in gastric juice, which is why early work focused on the stomach and intestines.
The version studied in the lab is manufactured synthetically. Its nickname in some communities, the “Wolverine peptide,” reflects interest in tissue repair, not proven clinical results.
| Feature | Detail |
|---|---|
| Full name | Body Protection Compound-157 |
| Length | 15 amino acids |
| Origin of sequence | Protective protein in human gastric juice |
| Regulatory status | Research compound; not FDA-approved |
How BPC-157 is thought to work
Researchers have proposed several overlapping mechanisms. None has been confirmed as the sole explanation, and most were observed in cell or animal models.
Blood-vessel growth (angiogenesis)
The peptide appears to encourage new vessel formation, which could improve blood supply to damaged tissue. Better perfusion is a common theme across tendon and gut studies.
Nitric oxide signaling
Nitric oxide influences vessel tone and inflammation. BPC-157 has been reported to modulate this pathway, which may help explain its varied effects.
Growth factor expression
Studies describe higher expression of repair-related growth factors, including VEGF and EGF, after exposure to the peptide.
Collagen production
Collagen is the main structural protein in tendon, ligament and skin. Support for collagen synthesis is one proposed reason for the interest in connective tissue.
What the research reports
The areas below are where preclinical studies cluster. Findings in animals do not guarantee the same outcome in people.
Tendons and ligaments
- Achilles tendon injury models
- Rotator cuff-type injuries
- Medial and anterior cruciate ligament models
- Muscle-to-tendon healing
Digestive tract
- Stomach ulcer models
- Intestinal damage and inflammatory bowel models
- Possible involvement of the gut-brain axis
Bone and joint
- Fracture healing in animals
- Cartilage and joint inflammation models
Dosing ranges reported in research protocols
Signal IQ’s BPC-157 compound page summarizes the ranges used in research settings. These are descriptions of the literature, not personal recommendations.
| Phase | Reported range | Schedule |
|---|---|---|
| Maintenance | 500 mcg (10 units on a 5 mg/mL vial) | Once daily, 5 days on and 2 off, or every other day |
| Loading | 1 mg (20 units) | Once daily for 10 days, then maintenance |
| Cycle length | 8 to 12 weeks, or until the research objective is met | |
Those unit figures assume a 10 mg vial mixed with 2 mL of bacteriostatic water. If the math is new to you, see how to reconstitute peptides and the guide to insulin syringe units.
Routes and sites
The published research protocols describe subcutaneous injection. For a systemic approach, the abdomen is a commonly named site. For a localized approach, the general subcutaneous area near the target region is described, not injection directly into injured tissue. Oral forms exist in the literature but are generally considered to have lower bioavailability and are discussed mainly for gut questions. Read more in peptide injection sites.
Timing is usually not critical. Evening dosing is mentioned, and fasting is sometimes used, but evidence that it is required is limited.
Safety and who should avoid it
Reported side effects are generally mild and include injection-site reactions, temporary nausea and, rarely, headache. Because the peptide is believed to promote angiogenesis, researchers raise theoretical concern about people with active cancer. Pregnancy and breastfeeding are also commonly listed as reasons for caution, as are certain autoimmune conditions.
Long-term human safety data are lacking. For a broader overview, read peptide side effects, and learn why labs treat many compounds as research use only.
Compounds often researched alongside BPC-157
BPC-157 is frequently discussed with TB-500 because both are studied for tissue repair through different routes. See the BPC-157 and TB-500 stack overview and the TB-500 guide. GHK-Cu is another common pairing; see the GHK-Cu guide. You can also browse options by goal on peptides by goal, or ask Pulse a question.
Frequently asked questions
How quickly does BPC-157 work?
There is no established timeline in humans. Anecdotal reports mention changes within a few weeks, but these are not controlled data. Research protocols typically run 8 to 12 weeks.
Does BPC-157 have to be injected near the injury?
Not necessarily. Systemic subcutaneous dosing is common in protocols, and a localized approach uses the general area near the target, not the injured tissue itself. Evidence comparing the two in people is limited.
Can BPC-157 be combined with other peptides?
It is often discussed alongside TB-500. Whether combinations add benefit has not been shown in rigorous human trials, and mixing in one syringe raises compatibility questions covered in this guide.
Is BPC-157 approved by the FDA?
No. It is not approved for any condition and is generally sold for laboratory research. Rules differ between countries.
How long should a BPC-157 cycle last?
Research protocols describe 8 to 12 weeks or until the objective is met. See peptide cycling for background on on-and-off scheduling.
Is BPC-157 safe?
Animal studies and anecdotal reports suggest it is generally well tolerated, but long-term human safety has not been established. Individual risk depends on health history, so discuss it with a clinician.
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



